Alan Anh-Chuong Nguyen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunophenotyping | 1 | 2024 | 1866 | 0.640 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2020 | 669 | 0.620 |
Why?
|
Granulomatous Disease, Chronic | 1 | 2016 | 176 | 0.500 |
Why?
|
Immunologic Deficiency Syndromes | 3 | 2024 | 548 | 0.460 |
Why?
|
Thorax | 1 | 2016 | 554 | 0.430 |
Why?
|
Flow Cytometry | 1 | 2024 | 5881 | 0.430 |
Why?
|
Eosinophilia | 1 | 2016 | 556 | 0.390 |
Why?
|
Prednisone | 1 | 2016 | 1565 | 0.390 |
Why?
|
T-Lymphocytes | 3 | 2024 | 10261 | 0.360 |
Why?
|
Immunologic Factors | 1 | 2020 | 1587 | 0.360 |
Why?
|
B-Lymphocytes | 1 | 2024 | 4778 | 0.360 |
Why?
|
Anti-Inflammatory Agents | 1 | 2016 | 1808 | 0.280 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2021 | 622 | 0.250 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 297 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
Antibody-Dependent Enhancement | 1 | 2020 | 15 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.170 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 323 | 0.150 |
Why?
|
Immunization, Passive | 1 | 2020 | 616 | 0.140 |
Why?
|
Inflammation | 1 | 2016 | 10850 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 547 | 0.130 |
Why?
|
Lymphopenia | 1 | 2019 | 297 | 0.130 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2019 | 235 | 0.130 |
Why?
|
Adaptive Immunity | 1 | 2020 | 734 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1789 | 0.110 |
Why?
|
Neonatal Screening | 1 | 2019 | 627 | 0.110 |
Why?
|
Biological Products | 1 | 2021 | 942 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1880 | 0.090 |
Why?
|
Phagocytosis | 1 | 2016 | 1520 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2021 | 3050 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2822 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2712 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2020 | 3081 | 0.070 |
Why?
|
Gene Expression | 1 | 2020 | 7584 | 0.070 |
Why?
|
Child, Preschool | 5 | 2023 | 42500 | 0.070 |
Why?
|
Hospitalization | 1 | 2023 | 10808 | 0.050 |
Why?
|
Asthma | 1 | 2021 | 6270 | 0.050 |
Why?
|
Humans | 10 | 2024 | 765968 | 0.050 |
Why?
|
Interleukin-6 | 2 | 2021 | 3222 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 13076 | 0.050 |
Why?
|
Cohort Studies | 1 | 2023 | 41649 | 0.040 |
Why?
|
Azetidines | 1 | 2021 | 150 | 0.040 |
Why?
|
Macrophage Activation Syndrome | 1 | 2020 | 124 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18071 | 0.040 |
Why?
|
Child | 4 | 2023 | 80564 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 428 | 0.040 |
Why?
|
Purines | 1 | 2021 | 615 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 81514 | 0.030 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 537 | 0.030 |
Why?
|
Autoimmunity | 1 | 2023 | 1354 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1183 | 0.030 |
Why?
|
California | 1 | 2019 | 1436 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20659 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1461 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1736 | 0.020 |
Why?
|
Sulfonamides | 1 | 2021 | 1984 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2226 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 2033 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2268 | 0.020 |
Why?
|
Male | 5 | 2023 | 363698 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2023 | 4405 | 0.020 |
Why?
|
Infant | 2 | 2023 | 36386 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10070 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14652 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7421 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22223 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2021 | 9249 | 0.010 |
Why?
|
Adolescent | 2 | 2023 | 88835 | 0.010 |
Why?
|
Female | 4 | 2023 | 396112 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29922 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 26346 | 0.010 |
Why?
|
Young Adult | 1 | 2023 | 59889 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2021 | 65188 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 74840 | 0.010 |
Why?
|
Aged | 1 | 2023 | 171117 | 0.010 |
Why?
|
Middle Aged | 1 | 2023 | 223009 | 0.000 |
Why?
|
Adult | 1 | 2023 | 223044 | 0.000 |
Why?
|